The latest version introduces a high-powered field of view designed to elevate the diagnostic experience for pathologists, along with a dedicated tumor board workflow module.
Read More
PROSTOX ultra identifies patients at higher risk of developing late genitourinary toxicity from stereotactic body radiation therapy.
Read More
Study finds molecular signature identifies which men with recurrent disease respond to apalutamide plus salvage radiation therapy.
Read More
First Ascent Biomedical is validating a live-cell testing platform that screens over 150 FDA-approved therapies against a patient’s tumor, generating individualized treatment insights in about 10 days.
Read More
The 2,400-patient study evaluates the Percepta Nasal Swab test’s ability to guide management decisions for patients with lung nodules.
Read More